Keros Announces US FDA Orphan Drug Designation Granted To KER-065
ReutersAug 20, 2025 3:40 PM
Aug 20 (Reuters) - Keros Therapeutics Inc KROS.O:
KEROS ANNOUNCES U.S. FDA ORPHAN DRUG DESIGNATION GRANTED TO KER-065 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
[Reuters Analysis] Trump adopts messenger-in-chief role after Charlie Kirk's death
By Trevor Hunnicutt and Steve Holland WASHINGTON, Sept 14 (Reuters) - Since the U.S. conservative activist Charlie Kirk was shot in a brazen display of violence, President Donald Trump has embraced the role of spokesman in an extraordinary way.Trump was first to confirm the news to a country in sReuters
19 minutes ago
[Reuters Breakingviews] China has yet to win the global power struggle
By Hugo Dixon LONDON, Sept 14 (Reuters Breakingviews) - Back-to-back spectacles this month may have given the impression that Beijing’s superpower struggle with the United States is all but over. First, India’s Narendra Modi and Vladimir Putin of Russia held hands as they walked to meet Xi JinpinReuters
26 minutes ago
Apple's New Products May Help the Stock, but Services Matter Most Heading Into Fiscal 2026
Key PointsApple's latest iPhones and wearables refresh the lineup, but the higher-margin services business is doing the real heavy lifting.Services now account for close to one-third of the tech giant's revenue, with materially higher margins than hardware.The stock's premium valuation means the invThe Motley Fool
32 minutes ago
Fed to Cut Rates: All Asset Prices Up!
TradingKey - The Federal Reserve is almost certain to restart its interest rate cut cycle on 17 September this year. After in-depth research, we have concluded that cryptocurrencies, the broader U.S. stock market, and short-term U.S. Treasury bonds will all go up.TradingKey
Mon, Sep 8
.jpg)
Tradingkey
